Breaking News

Financial Reports: Alexion

April 25, 2013

Soliris continues to rise

Alexion 1Q13

1Q Revenues: $339 million (+38%)

1Q Earnings: $82 million (+81%)

Comments: Sales of Soliris climbed 38% to $339 million, adding patients for both paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) indications. R&D expenses climbed 64% to $75 million as the company advanced five clinical programs, including one with Soliris.
blog comments powered by Disqus
  • A Biologic Innovator

    A Biologic Innovator's Pursuit to Uphold Patents

    Kristin Brooks, Contract Pharma||October 12, 2015
    Amgen v. Sandoz biosimilars litigation could impact the industry for years to come

  • BIO 2011 Wrapup

    Gil Roth||July 20, 2011
    Video interviews from the world's biggest biotech show